12/5
09:00 am
jazz
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Neutral
Report
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
12/3
04:31 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
04:26 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
12/2
04:05 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
11/27
07:07 pm
jazz
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
Low
Report
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
11/27
02:49 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
07:31 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
11/24
07:19 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
11/18
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
11/18
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
11/18
02:27 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
11/18
11:04 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
Medium
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
11/18
02:25 am
jazz
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence [Seeking Alpha]
Medium
Report
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence [Seeking Alpha]
11/18
02:25 am
jazz
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise [Seeking Alpha]
Medium
Report
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise [Seeking Alpha]
11/18
12:49 am
jazz
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial [Yahoo! Finance]
Medium
Report
Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial [Yahoo! Finance]
11/17
02:09 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
11/17
12:37 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an "overweight" rating on the stock.
11/17
11:56 am
jazz
Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today [Yahoo! Finance]
Low
Report
Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today [Yahoo! Finance]
11/17
06:53 am
jazz
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
Medium
Report
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
11/17
06:00 am
jazz
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
High
Report
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
11/16
02:27 am
jazz
Is Jazz Pharmaceuticals a Hidden Opportunity After 14% Climb and Expansion in 2025? [Yahoo! Finance]
High
Report
Is Jazz Pharmaceuticals a Hidden Opportunity After 14% Climb and Expansion in 2025? [Yahoo! Finance]
11/12
02:39 am
jazz
The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call [Yahoo! Finance]
Low
Report
The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call [Yahoo! Finance]
11/11
04:10 pm
jazz
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know [Yahoo! Finance]
Low
Report
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know [Yahoo! Finance]
11/11
08:01 am
jazz
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 [Yahoo! Finance]
Medium
Report
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 [Yahoo! Finance]
11/11
07:45 am
jazz
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Medium
Report
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025